{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:32:09Z","timestamp":1787877129849,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG066468"],"award-info":[{"award-number":["P30 AG066468"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AG025204"],"award-info":[{"award-number":["P01 AG025204"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG083874"],"award-info":[{"award-number":["R01 AG083874"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68372-w","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:54:38Z","timestamp":1769111678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4579-4057","authenticated-orcid":false,"given":"Yijun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Olvera-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Trivi\u00f1o-Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Solis-Urra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"G\u00f3mez- R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-8070","authenticated-orcid":false,"given":"Lauren E.","family":"Oberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur F.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-5612","authenticated-orcid":false,"given":"Charles H.","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-8954","authenticated-orcid":false,"given":"Jeffrey M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Marsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaeryon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Ikonomovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8014","authenticated-orcid":false,"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8546-8256","authenticated-orcid":false,"given":"Oscar L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-1770","authenticated-orcid":false,"given":"Irene","family":"Esteban-Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk I.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"68372_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Target. Ther. 8, 248 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"68372_CR2","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol. Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry"},{"key":"68372_CR3","doi-asserted-by":"crossref","unstructured":"Dubois, B. et al. Alzheimer disease as a clinical-biological construct\u2014an international working group recommendation. JAMA Neurol.81, 1304\u20131311 (2024).","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"68372_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dementia 20, 5143\u20135169 (2024). p.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR5","doi-asserted-by":"publisher","first-page":"e00570","DOI":"10.1016\/j.neurot.2025.e00570","volume":"22","author":"JL Cummings","year":"2025","unstructured":"Cummings, J. L. Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer\u2019s disease: Strategies and research directions. Neurotherapeutics 22, e00570 (2025).","journal-title":"Neurotherapeutics"},{"key":"68372_CR6","doi-asserted-by":"crossref","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimer\u2019s Dis. 10, 362\u2013377 (2023).","DOI":"10.14283\/jpad.2023.30"},{"key":"68372_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/healthcare11010032","volume":"11","author":"A Rashad","year":"2022","unstructured":"Rashad, A. et al. Donanemab for Alzheimer\u2019s disease: a systematic review of clinical trials. Healthcare 11, 32 (2022).","journal-title":"Healthcare"},{"key":"68372_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"68372_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol. Neurodegener. 18, 18 (2023).","journal-title":"Mol. Neurodegener."},{"key":"68372_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/YCO.0000000000000851","volume":"36","author":"WG Balogun","year":"2023","unstructured":"Balogun, W. G. et al. Plasma biomarkers for neurodegenerative disorders: ready for prime time? Curr. Opin. Psychiatry 36, 112\u2013118 (2023).","journal-title":"Curr. Opin. Psychiatry"},{"key":"68372_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"68372_CR12","first-page":"434","volume":"144","author":"A Keshavan","year":"2021","unstructured":"Keshavan, A. et al. Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70. Brain 144, 434\u2013449 (2021).","journal-title":"Brain"},{"key":"68372_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375 (2021).","journal-title":"JAMA Neurol."},{"key":"68372_CR14","first-page":"e688","volume":"98","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology 98, e688\u2013e699 (2022).","journal-title":"Neurology"},{"key":"68372_CR15","doi-asserted-by":"publisher","first-page":"fcaa041","DOI":"10.1093\/braincomms\/fcaa041","volume":"2","author":"SC Burnham","year":"2020","unstructured":"Burnham, S. C. et al. Longitudinal evaluation of the natural history of amyloid-\u03b2 in plasma and brain. Brain Commun. 2, fcaa041 (2020).","journal-title":"Brain Commun."},{"key":"68372_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimer\u2019s Dementia 21, e70038 (2025).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14536","volume":"21","author":"X Zhong","year":"2025","unstructured":"Zhong, X. et al. Plasma p-tau217 and p-tau217\/A\u03b21-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice. Alzheimer\u2019s Dementia 21, e14536 (2025).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR18","doi-asserted-by":"publisher","first-page":"e14430","DOI":"10.1002\/alz.14430","volume":"21","author":"M Olvera-Rojas","year":"2025","unstructured":"Olvera-Rojas, M. et al. Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/A\u03b242. Alzheimer\u2019s Dementia 21, e14430 (2025).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70409","volume":"21","author":"A Sehrawat","year":"2025","unstructured":"Sehrawat, A. et al. Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer\u2019s disease in the community. Alzheimer\u2019s Dementia 21, e70409 (2025).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR20","doi-asserted-by":"crossref","unstructured":"Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148, 416\u2013431 (2024).","DOI":"10.1093\/brain\/awae346"},{"key":"68372_CR21","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimer\u2019s Dementia 20, 8074\u20138096 (2024).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1136\/jnnp-2021-327370","volume":"92","author":"JR Chong","year":"2021","unstructured":"Chong, J. R. et al. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: a focused review on recent advances. J. Neurol. Neurosurg. Psychiatry 92, 1231\u20131241 (2021). p.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"68372_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand, A. L. et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimer\u2019s Res. Therapy 14, 195 (2022).","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"68372_CR24","doi-asserted-by":"publisher","first-page":"e14619","DOI":"10.1002\/alz.14619","volume":"21","author":"KR Sewell","year":"2025","unstructured":"Sewell, K. R. et al. Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits. Alzheimer\u2019s Dementia 21, e14619 (2025).","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR25","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer\u2019s disease plasma biomarkers. J. Neurochem. 168, 2736\u20132750 (2024).","DOI":"10.1111\/jnc.16130"},{"key":"68372_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-019-9237-1","volume":"16","author":"KK Dey","year":"2019","unstructured":"Dey, K. K. et al. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer\u2019s disease. Clin. Proteom. 16, 16 (2019).","journal-title":"Clin. Proteom."},{"key":"68372_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3, G. et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer\u2019s Res. Ther. 11, 27 (2019).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"68372_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimer\u2019s Dementia 15, 205\u2013216 (2019). p.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"68372_CR29","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240\u20131249 (2015).","journal-title":"Neurology"},{"key":"68372_CR30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain 139, 1226\u20131236 (2016).","journal-title":"Brain"},{"key":"68372_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","volume":"16","author":"Y Niimi","year":"2024","unstructured":"Niimi, Y. et al. Combining plasma A\u03b2 and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimer\u2019s Res. Ther. 16, 115 (2024).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"68372_CR32","doi-asserted-by":"publisher","first-page":"e0218077","DOI":"10.1371\/journal.pone.0218077","volume":"14","author":"MF Rocca","year":"2019","unstructured":"Rocca, M. F. et al. Utility of platforms Viteks MS and Microflex LT for the identification of complex clinical isolates that require molecular methods for their taxonomic classification. PLoS ONE 14, e0218077 (2019).","journal-title":"PLoS ONE"},{"key":"68372_CR33","unstructured":"Food, U. & D. Administration, 510 (k) substantial equivalence determination decision summary. AlloMap\u00ae Molecular Expression Testing. K, 73482. (2013)."},{"key":"68372_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1044-0305(01)00336-1","volume":"13","author":"AN Krutchinsky","year":"2002","unstructured":"Krutchinsky, A. N. & Chait, B. T. On the mature of the chemical noise in MALDI mass spectra. J. Am. Soc. Mass Spectrom. 13, 129\u2013134 (2002).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"68372_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.carres.2006.03.005","volume":"341","author":"K Busse","year":"2006","unstructured":"Busse, K. et al. The signal-to-noise ratio as a measure of HA oligomer concentration: a MALDI-TOF MS study. Carbohydrate Res. 341, 1065\u20131070 (2006).","journal-title":"Carbohydrate Res."},{"key":"68372_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/jalm\/jfaa225","volume":"6","author":"T Iino","year":"2021","unstructured":"Iino, T. et al. Quantification of amyloid-\u03b2 in plasma by simple and highly sensitive immunoaffinity enrichment and LC-MS\/MS assay. J. Appl. Lab. Med. 6, 834\u2013845 (2021).","journal-title":"J. Appl. Lab. Med."},{"key":"68372_CR37","doi-asserted-by":"publisher","first-page":"105832","DOI":"10.1016\/j.cct.2019.105832","volume":"85","author":"KI Erickson","year":"2019","unstructured":"Erickson, K. I. et al. Investigating gains in neurocognition in an intervention trial of exercise (IGNITE): protocol. Contemp. Clin. Trials 85, 105832 (2019).","journal-title":"Contemp. Clin. Trials"},{"key":"68372_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement"},{"key":"68372_CR39","doi-asserted-by":"publisher","first-page":"1168549","DOI":"10.3389\/fnhum.2023.1168549","volume":"17","author":"P Solis-Urra","year":"2023","unstructured":"Solis-Urra, P. et al. Active gains in brain using exercise during aging (AGUEDA): protocol for a randomized controlled trial. Front. Hum. Neurosci. 17, 1168549 (2023).","journal-title":"Front. Hum. Neurosci."},{"key":"68372_CR40","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1212\/WNL.55.12.1854","volume":"55","author":"OL Lopez","year":"2000","unstructured":"Lopez, O. L. et al. Research evaluation and diagnosis of probable Alzheimer\u2019s disease over the last two decades: I. Neurology 55, 1854\u20131862 (2000).","journal-title":"Neurology"},{"key":"68372_CR41","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/WNL.55.12.1863","volume":"55","author":"OL Lopez","year":"2000","unstructured":"Lopez, O. L. et al. Research evaluation and diagnosis of possible Alzheimer\u2019s disease over the last two decades: II. Neurology 55, 1863\u20131869 (2000).","journal-title":"Neurology"},{"key":"68372_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00711-1","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng, X. et al. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Mol. Neurodegener. 19, 40 (2024).","journal-title":"Mol. Neurodegener."},{"key":"68372_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/10408340500526766","volume":"36","author":"AG Asuero","year":"2006","unstructured":"Asuero, A. G., Sayago, A. & Gonz\u00e1lez, A. The correlation coefficient: An overview. Crit. Rev. Anal. Chem. 36, 41\u201359 (2006).","journal-title":"Crit. Rev. Anal. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68372-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68372-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68372-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:02:05Z","timestamp":1771297325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68372-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68372"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68372-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4947448\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.C., X.Z., N.A.Y., and T.K.K. are named inventors on US and worldwide patents filed by the University of Pittsburgh on the streamlined plasma A\u03b2 method described in this manuscript. Disclosure title: \u201cMethod for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer\u2019s Disease;\u201d US Application No.: 63\/672,952; PCT Serial No.: PCT\/IB2025\/057270; Current stage: International search report and written opinion of the international searching authority. The specific aspects of the manuscript covered in the patent application include the streamlined plasma A\u03b2 method and its improved clinical performance. TKK has served as an adhoc consultant and\/or advisory board member for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., Alzheon, Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. T.K.K. is an inventor on patents and provisional patents regarding biofluid biomarker methods, targets and reagents\/compositions, that may generate income for the institution and\/or self should they be licensed and\/or transferred to another organization. T.K.K. has received royalties from Bioventix for the transfer of specific antibodies and blood biomarker assays to third-party organizations. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1673"}}